Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2011

View Archived Issues

Sinovac Biotech obtains GMP certificate in Mexico for two vaccines

Takeda antioxidant response element activator shows promise in experimental colitis

CHDI Foundation discloses new kynurenine 3-monooxygenase inhibitors

Hungarian company presents novel agents for tuberculosis

New agent exploits Warburg effect and shows promise in renal cell cancer models

Acetylon Pharmaceuticals prepares novel HD6 inhibitors

Novel beta-secretase 1 inhibitors synthesized by Amgen

NIH to support studies of Lpath immunotherapy in diabetic neuropathy

New voltage-gated sodium channel modulators presented by GSK

Primary endpoints met in phase III trial of Hisamitsu Pharmaceutical oxybutynin formulation

NexBio reports data from phase II trial of DAS-181

Omthera Pharmaceuticals begins phase III ESPRIT trial

Pulmatrix secures funding for COPD and CF programs

NanoViricides' lead HIVCide shows sustained anti-HIV effects in animal study

FDA extends review of Regeneron's BLA for Eylea

FDA approved new strengths of Lupron Depot-PED allowing administration every 3 months

Nabi Biopharmaceuticals receives another milestone payment from Fresenius

Genetically altered T cells eradicate chronic lymphocytic leukemia cells in patients

New compounds reported for hepatitis C

PharmAthene receives Department of Defense contract for nerve agent medical countermeasure program

Kuros Biosurgery advances European trial of dural sealant KUR-023

Clavis reports interim results from phase II trial of elacytarabine/idarubicin combination

Rhythm Pharmaceuticals begins phase I study in diabetic gastroparesis

Qiagen and Pfizer collaborate on companion diagnostic for investigational lung cancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.